Table 4 Association between CYP3A5 phenotype and laboratory or electrocardiogram values

From: Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study

Lab Test

Difference at mid-cycle of C1

SD

p value

Difference at end of C1

SD

p value

CYP3A5 IM/PM

CYP3A5 NM

CYP3A5 IM/PM

CYP3A5 NM

ALT (U/L)

−1 (−8, 2)

−4 (−9, 4)

−0.21

0.78

−7 (−10, 3)

−5 (−9, 6)

−0.36

0.56

AST (U/L)

0 (−5, 2)

−2 (−6, 3)

0.54

0.71

−2 (−6, 5)

−2 (−6, 13)

0.51

0.88

QTc (ms)

9 (−5, 20)

18 (−2, 46)

0.07

0.54

3 (−1, 28)

16 (−21, 27)

−0.45

0.80

ANC (1000/mm3)

−2 (−2, 0)

−3 (−4, −1)

−1.1

0.09

−2 (−2, −1)

−3 (−6, −2)

−1.1

0.10

  1. ALT alanine aminotransferase, ANC absolute neutrophil count, AST aspartate aminotransferase, C1 cycle 1, IM/NM intermediate metabolizers/normal metabolizers, PM poor metabolizers, SD: standard deviation
  2. Median and interquartile range are shown for continuous data.
  3. SD represents the standardized difference in CYP3A5 poor metabolizers minus the CYP3A5 IM/PM for the change in each endpoint (post minus baseline).
Back to article page